Study summary

The primary purpose of this study is to evaluate the tolerability and safety profile of ASP1951 when administered as a single agent and in combination with pembrolizumab in participants with locally advanced (unresectable) or metastatic solid tumors; characterize the pharmacokinetic profile of ASP1951 when administered as a single agent and in combination with pembrolizumab; and determine the recommended phase 2 dose (RP2D) of ASP1951 and/or maximum tolerated dose (MTD) when administered as a single agent and in combination with pembrolizumab. This study will also evaluate the anti-tumor effect of ASP1951 when administered as a single agent and in combination with pembrolizumab.

Additional Study Details

Phase
Phase 1
Product
  • ASP1951
  • pembrolizumab
  • Type
    Interventional
    Masking
    None (Open Label)
    Enrollment number
    119
    Show Additional Study Details

    Study documents

    Scientific Results Summary
    Available Language(s): English
    Plain Language Summary
    Available Language(s): English

    Get more information

    Would you like more information about clinical trial sites that are recruiting participants for A Study of ASP1951 in Subjects with Advanced Solid Tumors? Contact us by filling out your information to the right and we’ll respond to you.

    • A patient
    • A caregiver
    • A parent
    • A healthcare provider
    • A patient advocate
    • Algeria
    • Argentina
    • Armenia
    • Australia
    • Austria
    • Belarus
    • Belgium
    • Bosnia And Herzegovina
    • Brazil
    • Bulgaria
    • Canada
    • Chile
    • China
    • Colombia
    • Croatia
    • Czech Republic
    • Denmark
    • Dominican Republic
    • Egypt
    • Estonia
    • Finland
    • Former Serbia and Montenegro
    • France
    • Georgia
    • Germany
    • Greece
    • Guatemala
    • Hong Kong
    • Hungary
    • Iceland
    • India
    • Indonesia
    • Ireland
    • Israel
    • Italy
    • Japan
    • Jordan
    • Kazakhstan
    • Latvia
    • Lebanon
    • Lithuania
    • Macedonia
    • Malaysia
    • Mexico
    • Montenegro
    • Morocco
    • Netherlands
    • New Zealand
    • Norway
    • Panama
    • Peru
    • Philippines
    • Poland
    • Portugal
    • Puerto Rico
    • Republic of Korea
    • Republic of Moldova
    • Romania
    • Russian Federation
    • Saudi Arabia
    • Serbia
    • Singapore
    • Slovakia
    • Slovenia
    • South Africa
    • Spain
    • Sweden
    • Switzerland
    • Taiwan, Province of China
    • Thailand
    • Turkey
    • Ukraine
    • United Kingdom
    • United States
    • Vietnam

    By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

      Locations

      Contact Us
      Contact Us
      Completed
      Multicare Regional Cancer Center Tacoma
      Tacoma, WA, United States, 98405
      Completed
      Comprehensive Cancer Nevada
      Las Vegas, Nevada, United States, 89169
      Completed
      South Texas Accelerated Research Therapeutics, LLC
      San Antonio, TX, United States, 78229
      Completed
      Virginia Cancer Specialists
      Fairfax, VA, United States, 22031
      Completed
      Emory University
      Atlanta, Georgia, United States, 30322
      Completed
      University of California
      Sacramento, California, United States, 95817
      Completed
      Columbia University Medical Center
      New York, New York, United States, 10032
      Completed
      University of Iowa Hospitals
      Iowa City, IA, United States, 52242
      Completed
      Site KR82003
      Seoul, Republic of Korea
      Completed
      Site KR82005
      Daegu, Republic of Korea
      Completed
      Site KR82002
      Chungcheongbukdo, Republic of Korea
      Completed
      Site KR82004
      Seoul, Republic of Korea
      Completed
      Henry Ford Health System
      Detroit, MI, United States, 48202
      Completed
      Site TW88603
      Taichung, Taiwan, Province of China
      Completed
      Augusta University
      Augusta, GA, United States, 30912
      Completed
      Rush University Medical Center
      Chicago, IL, United States, 60612
      Completed
      Rutgers Cancer Institute
      New Brunswick, New Jersey, United States, 08903
      Completed
      University of Florida, Davis C
      Gainesville, Florida, United States, 326102
      Completed
      Site TW88604
      Taipei, Taiwan, Province of China
      Completed
      Site KR82007
      Seoul, Republic of Korea
      Completed
      Site CA15002
      Montreal, Canada
      Completed
      Site CA15005
      Montreal, Canada
      Completed
      Hollings Cancer Center
      Charleston, South Carolina, United States, 29425
      Withdrawn
      Start Midwest
      Grand Rapids, Michigan, United States, 49546
      Completed
      Northwestern University
      Chicago, Illinois, United States, 60611
      Completed
      Icahn school of Medicine at Mount Sinai
      New York, New York, United States, 10029
      Completed
      Duke University Medical Center
      Durham, NC, United States, 27705
      Withdrawn
      UC Irvine Medical Center
      Orange, California, United States, 92868
      Completed
      Site KR82001
      Gyeonggi-do, Republic of Korea
      Completed
      Site KR82006
      Seoul, Republic of Korea
      Completed
      Nebraska Cancer Specialists
      Omaha, Nebraska, United States, 68130
      Completed
      Arizona Clinical Research Cent
      Tuscon, AZ, United States, 85715
      Completed
      Huntsman Cancer Institute
      Salt Lake City, Utah, United States, 84112
      Completed
      Site CA15004
      Ontario, Canada

      Frequently Asked Questions

      Are clinical trials only for people with advanced cancer?

      While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

      Will I have to stop my current treatment to participate in a clinical trial?

      Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

      Should I be worried about getting a placebo?

      In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

      Do I need a referral from my doctor to take part in a study?

      Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

      Explore More

      1

      What are clinical trials?

      2

      Why are Clinical Trials Important?

      3

      Why Participate in a Clinical Trial?